StateHouse Holdings Past Earnings Performance
Past criteria checks 0/6
StateHouse Holdings's earnings have been declining at an average annual rate of -58.5%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 27.8% per year.
Key information
-58.5%
Earnings growth rate
7.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 27.8% |
| Return on equity | n/a |
| Net Margin | -223.7% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Slammed 42% StateHouse Holdings Inc. (CSE:STHZ) Screens Well Here But There Might Be A Catch
Mar 05
The Market Lifts StateHouse Holdings Inc. (CSE:STHZ) Shares 175% But It Can Do More
Jan 04Even With A 200% Surge, Cautious Investors Are Not Rewarding StateHouse Holdings Inc.'s (CSE:STHZ) Performance Completely
Sep 01StateHouse Holdings Inc.'s (CSE:STHZ) Shares Leap 200% Yet They're Still Not Telling The Full Story
Sep 01Revenue & Expenses BreakdownBeta
How StateHouse Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 101 | -226 | 57 | 0 |
| 30 Jun 23 | 106 | -229 | 62 | 0 |
| 31 Mar 23 | 116 | -241 | 70 | 0 |
| 31 Dec 22 | 108 | -240 | 65 | 0 |
| 30 Sep 22 | 98 | -72 | 56 | 0 |
| 30 Jun 22 | 84 | -49 | 45 | 0 |
| 31 Mar 22 | 65 | -34 | 33 | 0 |
| 31 Dec 21 | 60 | -26 | 31 | 0 |
| 30 Sep 21 | 58 | -4 | 32 | 0 |
| 30 Jun 21 | 59 | -9 | 32 | 0 |
| 31 Mar 21 | 59 | -12 | 30 | 0 |
| 31 Dec 20 | 60 | -12 | 28 | 0 |
| 30 Sep 20 | 59 | -52 | 28 | 0 |
| 30 Jun 20 | 53 | -51 | 27 | 0 |
| 31 Mar 20 | 50 | -55 | 31 | 0 |
| 31 Dec 19 | 47 | -49 | 32 | 0 |
| 30 Sep 19 | 36 | -5 | 27 | 0 |
| 30 Jun 19 | 34 | -8 | 27 | 0 |
| 31 Mar 19 | 27 | -8 | 21 | 0 |
| 31 Dec 18 | 21 | -18 | 19 | 0 |
| 30 Sep 18 | 25 | -18 | 20 | 0 |
| 31 Dec 17 | 15 | -6 | 11 | 0 |
| 31 Dec 16 | 6 | -3 | 7 | 0 |
Quality Earnings: STHZ is currently unprofitable.
Growing Profit Margin: STHZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STHZ is unprofitable, and losses have increased over the past 5 years at a rate of 58.5% per year.
Accelerating Growth: Unable to compare STHZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STHZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.4%).
Return on Equity
High ROE: STHZ's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.